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 Introduction 
 This chapter discusses raising the technological scope for locally manu-
facturing active pharmaceutical ingredients (APIs), excipients and 
biologicals in Africa – a hitherto nascent industry. It also discusses 
African drug development and manufacturing through the standardized 
use of ‘reverse pharmacology’ to bring new treatments for neglected 
diseases to the point of regulatory approvals. Currently there is very 
modest production of APIs on the African continent, although a few 
significant projects exist, 1 (such as LaGray in Ghana and Fine Chemicals 
in South Africa), or are in the planning stages. 2 Generic producers in 
India and China supply nearly all of the APIs used in African phar-
maceutical manufacturing. Most African companies cannot afford the 
heavy investment and research and development activities required for 
API production. 
 Two strategies are suggested to help to address these issues: first, the 
introduction of technology transfer (product development) packages 
at centres of excellence, with each package being transferred to several 
manufacturers; second, the use of ‘leap-frogging’ technologies to reduce 
capital investment, minimize the environmental footprint and enhance 
competitiveness. Leap-frogging technologies have the advantage that 
Africa can skip technology and investment legacy issues. Leap-frogging 
technologies can also narrow the gap between rich and poor economies 
in drug discovery/development and pharmaceutical manufacturing by 
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taking advantage of the rich diversity of natural products sources and 
indigenous knowledge in disease treatment. 
 In this chapter we tackle API, excipient and biologicals manufacture 
by considering the science, technology and human as well as institu-
tional and organizational capabilities needed to raise Africa’s techno-
logical levels in API, excipient and FPP manufacture. This chapter is 
informed by the laboratory and practice experience in API, excipients 
and biological manufacture. 
 APIs and excipients: important components of 
producing medicines 
 A medicine may be broadly defined as any substance or substances used 
in the treatment, diagnosis, prevention, mitigation or cure of a disease. 
Drug molecules that exert a biological effect are known as active phar-
maceutical ingredients (APIs). APIs alone are unsuitable for human use 
as medicines. Various additional ingredients (excipients) are formu-
lated in combination with APIs to manufacture finished pharmaceu-
tical products (FPPs). An FPP contains one or more APIs and is the form 
in which a medicine is presented to the patient. FPPs can be tablets, 
capsules, oral liquids (suspensions or solutions); creams/ointments for 
topical administration; injectable solutions; or patches, suppositories 
or inhaled-delivery forms. Some delivery forms are inherently easier 
than others to manufacture, but each combination of API and delivery 
form requires an individual development program to assure the iden-
tity, stability, safety, purity, potency and efficacy of the final product. 
The number of APIs used for the treatment of all human diseases is 
relatively small. The various major pharmacopoeial compendia (inter-
national, European, US or British) list fewer than 2,500 different APIs 
that are approved for use as medicines. APIs are formulated in order to 
assure their stability, uniformity and reproducibility, to enhance patient 
compliance and to maximize efficacy by optimizing dissolution, absorp-
tion and bioavailability. 
 APIs alone are unsuitable for direct patient dosing, because FPPs must 
be stable, convenient, palatable and uniform in their dosage and content. 
Since the amount of drug dissolved in stomach fluid after oral dosing is 
a direct measure of how much drug is available for absorption, the use 
of different excipients/formulations may control solubility and whether 
a drug is available for immediate release, extended/sustained release or 
even delayed release. Tablets typically contain 20–60% loading of API 
content by weight. Pre-formulation studies involve the evaluation and 
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establishment of target ranges for the physicochemical properties of an 
API (salt selection, crystal form, particle size distribution [PSD]and level 
of hydration/solvation). 
 Every solid oral dosage form contains at a minimum excipients that 
serve as a binder, filler, lubricant and disintegrant. Excipients that 
serve as surfactants, compression aids, desiccants, glidants, dissolution 
enhancers, taste modifiers, colorants and coatings are also very often 
employed. Many hundreds of excipients of various types are used in 
pharmaceutical formulations. These ingredients are generally regarded 
as safe (GRAS) when present below established permissible daily expo-
sure (PDE) limits. Quality by design (QbD) at this stage involves careful 
evaluation and selection of critical quality attributes (CQAs) of the API, 
and matching of the desired performance characteristics of the FPP with 
selection and grade of excipients used. 
 Table 7.1 shows a range of excipients commonly used in FPPs, typi-
cally used as weight percentages of a tablet, and price ranges (prices 
obtained from import-export data at  www.infodriveindia.com ). If these 
costs are compared with API pricing in Table 7.2, it is readily seen that 
excipients are normally much less expensive than APIs as a contribution 
to the cost of producing FPPs. 
 For solid oral FPP manufacturing the API and excipients are blended 
together, often as powders with unlike properties. Along with blending, 
there is a massing process of bringing these powders together to form 
larger particles of uniform content, known as granules. Wet granulation 
is possibly the most commonly used technique for granulation. Although 
this process is very reliable, a subsequent drying step is required that is 
both process intensive and must be carefully controlled so as not to 
cause risk of degradation. Granules are either filled into hard gelatin 
capsules or compressed into tablets. Tablets may be coated in order to 
improve their appearance, impart distinctive identifying characteristics 
or enhance stability. Compression into tablets does not destroy gran-
ules. The disintegration of tablets in the stomach after ingestion releases 
these granules at an early step in the process of dissolution and absorp-
tion of drugs. Soft gelatin capsules are filled with a solution or suspen-
sion of API(s) in a liquid-fill process, and the technology used for these 
formulations is somewhat specialized. 
 Manufacturing active pharmaceutical ingredients 
 Almost all small-molecule APIs are prepared by chemical synthesis, 
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plant sources. A number of APIs are produced by some combination 
of these techniques. Plant cultivation and extraction of the natural 
product artemisinin, for example, is combined with chemical synthesis 
to produce the anti-malarial APIs artemether and artesunate (USNLM, 
2014), as shown in Figure 7.1. 
 The cost of manufacturing an API depends on the raw material 
pricing, yield, processing time and volume efficiency of each manu-
facturing step. Other cost drivers are the cost of operating the manu-
facturing facility (overheads and labour: OHL) and capital investment 
required to build and equip the manufacturing plant. Overheads and 
labour include costs of personnel, energy, waste disposal, shipping and 
eventual cost of decommissioning the facility. Higher volume demand 
generally decreases the proportionate cost contribution of raw mate-
rials and overheads and labour. Substantial production volumes are 
therefore required to obtain full economy of scale (Jayaraman, 2012). 
Producing 1–5 metric tons per year is more expensive than producing 
100 metric tons of an API in appropriately sized facilities. The effi-
ciency of a synthesis is often quoted in terms of overall yield and as an 
E-factor (Sheldon, 2007) representing the kilograms of waste produced 
per kilogram of product manufactured. Waste management is expen-





















 Figure 7.1  Chemical synthesis to produce the anti-malarial APIs artemether and 
artesunate 
 Source : Compiled by authors 
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E-factor of an API synthesis reduces costs. With a continued growth of 
volume demand, improved chemistry and competition from multiple 
suppliers, the cost of raw materials and APIs can decrease over time. 
For example, the cost of the API for the HIV/AIDS drug efavirenz at 
launch by the originator company (Dupont Pharmaceuticals) in 1998 
was about $1,600/kg at a first-year demand of about 150 tons (Personal 
recollection from the author, JF). Generic producers in India estimated 
their API costs at about $1,100/kg upon first generic introduction in 
2005 (Personal communication, Mr D.R. Rao, Cipla). Currently, the API 
can be purchased for about $120/kg, a 13-fold decrease in cost of API in 
17 years (import-export data at  www.infodriveIndia.com ). Notably, the 
volume demand of efavirenz in 2015 is also estimated at about 2,000 
tons, since this drug is a standard component of first-line AIDS treat-
ment in low- and middle-income countries. 
 As a rule of thumb, the overall cost of raw materials for an efficient 
process will represent about 50–70% of the total cost of API manufac-
turing, signifying the important role of smart procurement. This rule 
of thumb is applicable to high-volume generic production of synthetic 
APIs. Smaller-volume APIs – those produced by fermentation or natural 
products extraction, or APIs used in sterile products – can have much 
higher proportionate cost contributions for overheads and labour and 
capital investment. The synthetic route of manufacturing the HIV/AIDS 
API tenofovir disoproxil fumarate (TDF) (Figure 7.2) is a typical example. 
The key raw materials – adenine, (R)-propylene carbonate (RPC), diethyl 
p-toluenesulfonyl(oxymethyl)phosphonate (DESMP), chloromethyl 
isopropyl carbonate (CMIC) and fumaric acid – contribute to the molec-
ular structure of the API. Each step uses multiple additional materials as 
solvents or reagents, which are omitted from this simplified synthesis 
scheme. 
 The final crystallization or precipitation step of API manufacturing is 
the stage at which the physicochemical properties of an API are deter-
mined and the last stage at which related substances (impurities) can be 
removed or reduced to acceptable limits. The crystalline form and PSD 
of an API are often critical to the formulation, dissolution, absorption 
and bioavailability of a drug. Bioavailability is the fraction of a drug dose 
that reaches systemic circulation (blood plasma) upon human dosing 
(USFDA). By definition, any drug is 100% bioavailable when adminis-
tered by injection. 
 API cost reductions reflect improvements in production effi-
ciency, procurement and economies of scale. The overall yield of TDF 
(Figure 7.2) from adenine was less than 25% when the generic product 
128 Fortunak, Ngozwana, Gebre-Mariam, Ellison, Watts, Emeje and Nytko
was launched in 2006; it is currently in the range of 43–54%, a doubling 
of efficiencies. During this time the API pricing of TDF has decreased by 
65% from more than $600/kg to about $210/kg. Undoubtedly a lot of 
research and development effort went into improving yields, reducing 
use of solvents and reagents and decreasing processing times (Ripin 
et al., 2010). Improved procurement – a critical finance capability (see 
Chapter 13) – greatly reduced the cost of most of the key raw materials; 
this was probably the biggest contributor to cost reductions (Jayaraman, 
2012). Table 7.2 provides a range for the per-kilogram pricing of the key 
raw materials for TDF synthesis. These prices are given for purchasing 
ton-scale amounts of each raw material in the timeframe of January–
December 2014 (import-export data available at  www.infodriveIndia.
com ). When generic versions of TDF were first launched in 2006, the 
pricing for both RPC and DESMP, for example, was more than $20/kg. 
 API costs are often the largest component of the overall cost of a corre-
sponding finished pharmaceutical product (FPP). API producers gener-
ally operate on smaller margins than FPP producers. A well-established, 
competitive market for anti-retroviral (ARV) APIs for the treatment of 
HIV/AIDS in low- and middle-income countries illustrates this. Target 





























































 Figure 7.2  Synthetic route for the manufacture of the API tenofovir disoproxil 
fumarate 
 Source : Compiled by the author 
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ARV drugs with several approved suppliers, however, can be far lower. It 
is generally agreed that margins for the well-established ARV APIs zido-
vudine (AZT) and lamivudine (3TC) do not exceed 10%. 
 Can Africa expand local production of APIs? 
 APIs are sold in bulk, typically as powder in a drum. Global demand for 
very common APIs such as paracetamol, erythromycin or ibuprofen is 
as high as 60,000 tons per year. Volume demand for most APIs is in the 
range of 10 to 500 tons per year. Economies of scale are important for 
both API and FPP production. A manufacturing facility must be oper-
ating at close to its full capacity to maximize operational efficiency. 
Companies that manufacture both APIs and FPPs possess a competi-
tive market advantage because there is one less commercial transaction 
where profit is taken in the value chain. 
 In order to be successful, African API production must be priced simi-
larly to that of Indian and Chinese competitors. The quality must also 
match or exceed the standards of competitor products in the market. 
Procurement information is becoming widely available, and therefore 
African producers potentially have access to knowledge of the best avail-
able pricing for raw materials. African producers are potentially able to 
obtain competitive pricing on APIs and key raw materials, because these 
items are not sold in huge quantities on a single-transaction basis. For 
solvents and reagents that require very large-volume purchases to obtain 
 Table 7.2  Raw Materials that contribute to the structure of the API tenofovir 
disoproxil fumarate (TDF) and their current commercial pricing 
 Raw Material 
 Price per Kg 
( ton scale) 
 Kgs used per Kg 
of TDF produced 
 Raw Material. 
Price Contribution
/kg of TDF 




 DESMP $6.40–6.98 1.22 $7.81–8.52
 CMIC $8.79–9.24 1.61 $14.15–14.88
 Fumaric Acid $1.53–1.87 0.23 $0.35–0.43
 Total: $48.23–53.65
 Source : Compiled by the author using data from  www.infodriveIndia.com , April 2012–July 
2014. 
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best pricing, however, African producers can be at a disadvantage rela-
tive to Indian and Chinese counterparts. 
 There are many products, however, for which it is realistic that Africa 
production can be price-competitive with India and China. Low-dose 
APIs are one set of medicines. Entecavir, for example, is a very useful 
product for the treatment of hepatitis B virus (HBV). Entecavir is also 
a very important drug for Africa, since the continent bears a very large 
share of the global burden for HBV. Entecavir is delivered at a dose of 
0.5 mg/day. At this extremely low dose, the API contribution to FPP 
pricing is potentially so small that the only important cost contribu-
tion to manufacturing an FPP is the inherent efficiency of formulating 
the tablet FPP. African pharmaceutical manufacturers do not, however, 
presently hold in their organizations the experienced, knowledgeable 
scientific staff to optimize API production processes in the same manner 
as Indian and Chinese producers are able to do. 
 African manufacturing of APIs and FPPs might be successful for a large 
range of moderately priced products that are no longer of high priority 
for Indian generics manufacturers. Many Indian companies target 
exports of more lucrative FPPs (such as gleevec or imatinib for cancer) 
and target high-priced markets in the US and Europe. For well-established 
generic products manufactured in large volumes, it is quite conceivable 
that African companies can purchase APIs at equal pricing to Indian FPP 
producers (Table 7.2). Metformin (diabetes), naproxen sodium (anal-
gesic), amoxicillin (anti-infective), metronidazole (anthelmintic) and 
lumefantrine (malaria) are examples. Under these circumstances, local 
manufacturing may actually be less expensive than importation because 
of differences in added-on pricing due to shipping and import duties. 
This aspect of pharmaceutical pricing is commonly overlooked. The 
associated costs of shipping and tariffs or other duties associated with 
importation of APIs or FPPs can readily amount to a 30% add-on for 
pricing; this can potentially create a pricing advantage for local manu-
facturing. International donor agencies that purchase essential medi-
cines for Africa and African national procurement programmes often do 
not take into account this potential advantage for local manufacturing 
when issuing tender offers for purchase. 
 ‘Leap-frogging’ technologies as opportunities for 
local API manufacture 
 Leap-frogging technologies are advances in manufacturing technology 
that provide large improvements over current techniques and avoid 
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legacies of industrial organic growth. These advances can be related to 
chemistry, formulations or techniques for manufacturing. Global phar-
maceutical companies are traditionally late adopters of new technolo-
gies because manufacturing costs are not closely tied to their product 
pricing or their profit model; furthermore, originator companies have 
huge investments in their current manufacturing facilities. For Indian 
companies, investment in new technologies can be unattractive unless 
it pays for the high cost of decommissioning existing ‘legacy’ manufac-
turing facilities. African companies do not largely suffer from such a high 
degree of captive ‘legacy’ investment in existing facilities. Continuous 
manufacturing of FPPs, for instance, is one area where African produc-
tion can be both environmentally and cost-preferred versus global 
competition. 
 A number of patents and publications (Chava et al., 2014; Datta et al., 
2014; Ripin et al., 2010) have disclosed information about TDF process 
optimizations that have reduced the API pricing by more than 70% since 
initial generic launch, as discussed earlier. New technologies for API 
production for TDF and EFV include biotechnology for the production 
of intermediates and ‘greener’ chemistry that reduces the E-factor of API 
production. In the case of EFV, this reduction is from about 55 to about 
12 (Bolu et al., 2012; Jian, 2008). Green chemistry (GC) includes the 
use of catalytic amounts of amino acids and their derivatives (organoca-
talysis) to reduce the number of steps and the cost of API processing. GC 
also includes continuous or ‘flow’ processing (Hebrault, 2014). Both of 
these technologies are in early stages of implementation and their full 
impact on API pricing is not yet being felt. 
 Flow chemistry is being used in one step of the commercial produc-
tion of an intermediate for the synthesis of the HIV-1 protease inhibitors 
atazanavir and darunavir (Pinho et al., 2014). Flow chemistry can be 
broadly summarized as an engineering approach to improved synthesis. 
Organocatalysis is a more chemistry-based approach to improved 
synthesis. Flow chemistry for commercial manufacturing is a special 
expertise owned by at least one African R&D centre, the Green Center 
for Chemical Manufacturing. Advanced technologies are not mutually 
exclusive and can often be employed together to improve API manufac-
turing efficiencies. 
 Taking advantage of these leap-frogging technology opportunities 
implies adoption of machinery, equipment and processes with higher 
efficiencies and lower environmental impact. This opportunity exists 
for African manufacturing of APIs. However, there is need for integra-
tion of API and FPP production to accommodate the scale needed for 
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API manufacture, requiring in turn financial incentives and supportive 
procurement to leveraging the huge intra-African medicines market. 
 Assuring the quality of APIs: Quality management systems 
and GMP 
 The quality of APIs and FPPs is assured by manufacturing under good 
manufacturing practice (GMP), including process validation, testing 
against previously established specifications and the demonstration 
of clinical bioequivalence (FDA, 2014). The investment and operating 
costs of a quality management system (QMS) for GMP contribute signifi-
cantly to the cost of pharmaceutical production. Producers must desig-
nate and justify to regulatory authorities a starting point or stage in the 
API synthesis from which GMP is applied. 
 Janice Berger, a well-known former USFDA field inspector, often 
remarked: ‘You’re either GMP or you’re NOT’. In a very real sense, this is 
the true. Companies cannot choose to move back and forth from GMP 
to non-GMP activities in the same manufacturing facility. The require-
ments for a QMS and documentation for GMP do not allow switches of 
this type. The general feeling in the industry is that additional invest-
ment in GMP compliance enables companies to gain market share and 
increase sales by differentiating them from their competitors based on 
quality. National drug regulatory agencies (NDRAs) bear the primary 
responsibility of working with companies to evolve their GMP prac-
tices to meet international standards (Chapter 12). The United States 
Pharmacopeia (USP) sponsors training programmes in GMP. Over the 
longer term, African nations must assume full responsibility for their 
own regulatory needs. The emerging Regulatory Sciences Institute 
(RSI) in South Africa is potentially an important player in promoting 
global standards for pharmaceutical manufacturing on the continent. 
It follows that a sustainable African generic pharmaceutical industry 
must be able to:
 develop products and processes meeting SRA standards of quality;  ●
 continuously manufacture under GMP;  ●
 compete with other quality-assured producers on price;  ●
 operate without legal encumbrances (dependent on intellectual  ●
property). 
 Regulatory sciences and rigorous product development are critical for 
obtaining generic drug approvals by SRAs. Originator companies employ 
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a very large number of skilled scientists to develop and launch new medi-
cines. One of us (JF) managed a scientific staff of over 350 chemists and 
engineers to support the filing of, on average, only 1–3 new marketing 
applications per year. Indian and Chinese generic companies also hold 
very substantial staff (60 or more development chemists) to launch 8–12 
new generic FPPs per year. Indian and Chinese generic companies also 
routinely outsource substantial R&D activities to regional centres of 
excellence (universities or technology development centres) to leverage 
their in-house capabilities. It is essential to build a pool of skills with 
capabilities in drug registration and regulation to support research and 
development as well as drug authorizations. 
 The IPAT program at the St. Luke Foundation / Kilimanjaro School 
of Pharmacy in Moshi, Tanzania is a UN ANDI Centre of Excellence 
training pharmaceutical and NDRA experts in GMP drug manufacturing, 
regulatory sciences and leap-frogging technologies since 2008. It was 
awarded a USFDA ‘Honor Award’ in 2013 for Excellence and Innovation 
in Regulatory Sciences training. The IPAT programme is partially funded 
by UNIDO and its approach has also been adopted by the University of 
Ibadan School of Pharmacy. 
 Opportunities for reverse pharmacology and traditional 
medicine for local drug development 
 Reverse pharmacology 
 Reverse pharmacology (RP) integrates traditional knowledge into drug 
discovery, development and production (Patwardan, 2009; Wambebe, 
2001). This approach identifies natural products or mixtures of natural 
products based on traditional knowledge combined with screening in 
biological assays. This green approach to drug discovery takes advan-
tage of cultural and ethno-botanical knowledge of a region to shortcut 
the lengthy, expensive, resource-intense process used in rational drug 
design. 
 The ‘hits’ identified by reverse pharmacology are further developed 
into drug candidates by exploratory studies including safety and activity 
testing, combined with clinical (human) dosing. During clinical devel-
opment, mixtures of compounds obtained as crude extracts are often 
used, but the classical activities of isolating compounds with biological 
activity and elucidating their structure remains a part of reverse pharma-
cology. The correlation of API content with biological activity, safety, the 
development and validation of analytical methods, process validation 
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and the setting of specifications for the active ingredients present are all 
steps in the RP process. 
 Drugs from traditional knowledge 
 Phytomedicines, or herbal medicines, are plants, herbs, extracts and 
purified natural products used for the prevention or treatment of disease, 
most often identified and derived from traditional knowledge. The regu-
latory requirements for approving phytomedicines are lower than for 
new chemical entities (NCEs), although the label claims for efficacy 
are also much more cautious. More than 80% of people in developing 
countries depend on herbal medicines (Iyamu, 2003; Patwardan, 2009; 
Perampaladas, 2010; Wambebe, 2001; Willcox, 2011). The World Health 
Organization has issued guidance on (1) quality assessment (WHO, 
2007), (2) pharmacovigilance (WHO, 2004) and (3) good manufacturing 
practices (WHO, 2007) for herbal medicines. However, processes to regu-
late the registration, approval and standardization of such products are 
only now being made universal (WHO, 2007). 
 Phytomedicines are typically purified by short, simple processes such 
as aqueous or aqueous alcoholic decoction, followed by solvent removal. 
This is very different from pharmaceutical natural product isolation 
from plants, such as the vinca alkaloids, taxol or camptothecins. These 
are typically present as much less than 1% of the dried weight of their 
respective plant sources and are purified by expensive, resource- intensive 
procedures. 
 Nigerian experience with Niprisan™ 
 A major centre for herbal medicines exists at the National Institute for 
Pharmaceutical R&D (NIPRD) in Nigeria. NIPRD utilizes a systematic 
approach to gathering, classifying, extracting, testing and identifying 
the therapeutic elements present in plant sources. A quality management 
system is in place at NIPRD, and standard operating procedures (SOPs) 
are followed by a multi-disciplinary team of scientists. This standardized 
approach has resulted in the launch of several effective medicines for 
treating malaria, sickle-cell anaemia, pain, inflammation and immuno-
logical diseases (Emeje, 2005; Emeje, 2011; Wambebe, 2001a; 2001b). 
The development of the herbal medicine Niprisan™ for treating sickle-
cell anaemia is described below. 
 Niprisan TM is a combined extract of four plants traditionally used in 
Nigeria to prevent sickle-cell disease (SCD) (Iyamu, 2003; Wambebe, 
2001). SCD is caused by a point mutation in the gene encoding for 
the beta globin chain of hemoglobin, distorting red blood cells into an 
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elongated, ‘sickled’ shape. SCD causes impaired circulation, tissue and 
organ damage, severe anaemia and increased mortality.  In vitro studies 
showed that Niprisan™ possesses potent anti-sickling effects. One or 
more of the active ingredients contained in Niprisan™ enhances the 
solubility of deoxy-HbS, retarding polymerization and increasing 
oxygen affinity (Wambebe, 2001). Controlled clinical trials conducted 
in Nigeria showed that Niprisan™ significantly reduces vaso-occlusion 
in SCD patients (Iyamu, 2003; Wambebe, 2001b). 
 Niprisan™ was standardized by extracting various seeds, fruits and 
stems from  Pterocarpus  osun, Sorghum  bicolor, Piper  guineensis and Eugenia 
 caryophyllum. Data from animal testing and using blood from sickle-
cell patients showed that the standard extracts prevent cell sickling. 
The safety of these extracts was demonstrated by animal testing before 
human use to demonstrate the absence of overt toxicities and lack of 
tissue and organ effects (Perampaladas, 2010; Wambebe, 2001a; 2001b). 
An initial human safety study was carried out in twenty patients, with 
the product already being used by thousands of people in Nigeria in an 
unstandardized product presentation (Wambebe 2001a). 
 Clinical phase II/III trials (in sickle-cell patients) using a capsule 
dosage form began about 18 months after the start of the discovery 
program at NIPRD. In that time, the product was identified, extracts 
were standardized, assays were developed, safety assessment was carried 
out, an initial manufacturing process was identified and clinical supplies 
were prepared. The extraction process for Niprisan™ is quite efficient, 
and extraction is not destructive of the cultivated plants. The dried 
extract represents about 20% of the collected biomass. One kilogram of 
Niprisan™ is therefore obtained utilizing about 5 kilograms of biomass 
and 10 litres each of water and ethanol. 
 A randomized, double-blind, placebo-controlled, crossover trial was 
conducted to support the approval of Niprisan™ (Perampaladas, 2010; 
Wambebe, 2001b). Patients with homozygous SCD in one group took the 
test drug (12 mg/kg body weight) daily for six months before crossing over 
to placebo for another six months. Another group took placebo for six 
months before crossing over to active drug for six months. There was a 
one-month washout period between crossovers. Niprisan™ use reduced 
the mean number of crises by 55% from placebo – a highly significant 
improvement (ρ < 0.05). Patients taking Niprisan™ generally rated their 
health as better and reported less sickness and absenteeism versus placebo. 
Apart from headache (12%), patients reported no significant adverse 
effects (Perampaladas, 2010; Wambebe, 2001a; 2001b). It was concluded 
that Niprisan™ was efficacious for the prophylactic management of SCD. 
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 SCD patients can, to a substantial degree, recognize the symptoms of 
impending SCD attacks. The occasional prophylactic use of Niprisan™ 
with chronic, intermittent dosing by approximately 90,000 people in 
Nigeria has resulted in the reduction of SCD attacks by 98% in this 
population. 
 Herbal extracts almost always contain several compounds, so the 
attribution of biological activity to a single particular compound can 
be difficult. Experience at NIPRD has shown that some phytomedi-
cines are more active as crude extracts than as purified entities. As in 
the case of Niprisan™, some extracts contain multiple closely related 
molecules with similar biological activity. Niprisan™ was approved by 
the Nigerian National Agency for Food and Drug Administration and 
Control (NAFDAC) in 2006 (see  http://nafdac.org.ng/ ). The estimated 
total discovery and development costs of Niprisan™ were approxi-
mately US$28 million (out-of-pocket), including US$8 million to build 
a manufacturing facility (Pandey, 2009). This figure is much lower than 
the figures for rational drug discovery and development. 
 The following conclusions can be offered when comparing reverse 
pharmacology with rational drug discovery and manufacturing:
 Medicines from traditional knowledge/reverse pharmacology can be  ●
standardized in production and demonstrated to be safe by current 
standards. 
 It is possible to prove that phytomedicines are effective in clinical  ●
trials. 
 Phytomedicines production can be much less expensive than  ●
common means of pharmaceutical production. 
 Reverse pharmacology can be highly effective and much less expen- ●
sive than rational drug design for discovery and development. 
 Not all emerging economies, especially those in Sub-Saharan Africa, 
can afford to extensively adopt rational drug design to discovering and 
developing new medicines for their unique health needs, whereas global 
pharmaceutical originator companies cannot invest heavily in neglected 
tropical diseases (NTDs). Reverse pharmacology is a much less expensive 
approach to drug discovery and pharmaceutical manufacturing. Failure 
rates in RP development are reduced by evidence of human safety from 
traditional use. Clinical trials using an RP approach are not as rigorous as 
those for rational drug discovery. Yet it is possible to design and success-
fully execute placebo-controlled, crossover studies to demonstrate clin-
ical efficacy for herbal medicines. Ultimately, drugs derived from RP are 
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more accessible and affordable than those from pharmaceutical origi-
nator companies, and some compromises must be made to provide new 
medicines for these significant, unmet medical needs. This only empha-
sizes the need for green chemistry in drug discovery, to make all valid 
forms of drug discovery much more efficient. 
 African capacity for API pharmaceutical manufacturing 
 South Africa has invested heavily in research of medical significance, 
with a large number of research units funded by the Medical Research 
Council. The country has worked to build the capacity for national 
pharmaceutical manufacturing of APIs and FPPs, as small-molecule 
biological therapeutics, largely through the Department of Trade and 
Industry (DTI). The national government has sustained, for example, 
an investment in BIOVAC for several years in an attempt both to 
minimize reliance on imported vaccines and to generate foreign 
exchange by export of vaccine products. BIOVAC is presently manu-
facturing the final stages of vaccine production for local and external 
use under license from at least one global, originator pharmaceutical 
company. 
 The only South African-based API manufacturer, Fine Chemicals 
Corporation (FCC) was founded in 1962 in Cape Town. At incep-
tion, FCC produced codeine phosphate, morphine sulphate and para-
cetamol exclusively for the South African market. The product range was 
expanded in the 1980s with the development of a number of generic 
APIs, primarily for the US market. In the 1990s, FCC invested heavily 
to meet emerging international standards of GMP production. Since 
then, the company has been successfully inspected by various regula-
tory authorities including the USFDA in 1996, 1999, 2002 and 2006. 
 The company currently has 79 installed reactors with a capacity of 
125,000 litres, with individual reactor capacities ranging from 100 
litres to 6,000 litres for glass-lined and stainless steel. The company 
has significant expertise internally and supplements this with partner-
ships with local and international contract research organizations and 
organizations with expertise in chiral separations and catalysis. The use 
of APIs is typically regulated by the filing of a drug master file (DMF) 
that fully describes the route of synthesis, controls, CQAs, testing and 
specifications. FCC has in excess of 150 DMF submission in more than 
16 countries around the world. Therapeutic uses for locally manufac-
tured APIs are as immunosuppressants, anticancer, muscle relaxants, 
anti-psychotics, anticholinergic, bronchodilators, carbonic anhydrase 
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inhibitors, analgesics, antihypertensive, antianginals and anaesthetics, 
among others. 
 Bioclones was founded in 1982 with the aim of developing mono-
clonal antibodies and manufacturing biotechnology-derived products 
for human use. The company became one of the first in the world to 
develop recombinant human erythropoietin, which was registered by 
the MCC in 1997 and marketed in South Africa in 1998. 
 LaGray Pharmaceuticals in Nsawam, Ghana, is unique among African 
pharmaceutical manufacturers. LaGray was founded in 2002 by Alexandra 
Graham and Paul Lartey, a wife-husband team with extensive experi-
ence in drug discovery, development and manufacturing of both APIs 
and FPPs in the global pharmaceutical industry. Dr. Lartey is the former 
director of anti-infective drug discovery at Pfizer Corp. Dr. Graham held 
several management positions at Abbott Labs. LaGray aims to differ-
entiate the company from its competitors by meeting international 
standards of GMP. LaGray products for topical use include a number of 
anti-infectives. The company’s early approach focussed on new prod-
ucts whose quality could be assured without the added investment of 
human bioequivalence trials. LaGray has implemented advanced proc-
esses for waste management and wastewater remediation, an area which 
is often ignored in African pharmaceutical manufacturing. LaGray is 
presently cooperating with the USP (United States Pharmacopeia) to 
train operators – the skilled workers who do the actual pharmaceutical 
manufacturing, a critical training need in West Africa. LaGray also has a 
small-scale manufacturing facility for APIs and is producing commercial 
amounts of the macrolide antibiotic azithromycin in Ghana. 
 Leap-frogging technologies and training in new 
technologies for competitive advantage 
 Manufacturing processes for APIs typically reflect the standard of chem-
istry available at the time the corresponding FPPs were first registered 
and approved for use. Although API processes evolve over time to give 
improved yields, reduce solvent use and reduce manufacturing time, 
the routes of synthesis generally are those as registered by originator 
companies. Malaria drugs are one therapeutic area for which this is 
true. Artemisinin combination therapies (ACTs) for malaria treatment 
consist of older drugs that were combined in fixed-dose combination 
or co-packaged FPPs for use. The Global Fund and other non-govern-
mental organizations sourced approximately 389 million ACT treat-
ments in 2013 (UNITAID, 2013). Artesunate: amodiaquine (ASAQ) and 
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dihydroartemisinin: piperaquine (DHAP) are two standard ACTs. ASAQ 
is the second-most used ACT behind artemether: lumefantrine (ALU). 
 The Kilimanjaro School of Pharmacy has trained participants in the 
IPAT program to synthesize these APIs during laboratory exercises in 
API manufacturing. Trainees have also used the API they synthesized 
to manufacture DHAP and ASAP FPPs in the Kilimanjaro School of 
Pharmacy pilot plant. One of us (JF) has created new chemistry for 
the synthesis of these two APIs that is used by participants in the IPAT 
training. One of these exercises has been published (Fortunak et al., 
2013). The new chemistry utilized for this purpose has simplified the 
manufacturing process for amodiaquine from five steps to two steps 
with no intermediate isolations; this synthesis is also readily adapted for 
continuous-flow chemical reactors (Fortunak, 2014). The overall yield 
of this synthesis is about 93% as compared with 65% for the previous 
route. New chemistry discovered for synthesizing piperaquine has the 
same number of steps as the commercial synthesis, but completely elim-
inates the presence of a genotoxic impurity previously present at a level 
of more than 2% in an intermediate stage of the synthesis. This has 
allowed an overall improvement in the E-factor of the synthesis from 
more than 45-plus kilograms of waste to approximately 8 kg of waste 
generated per kilogram of API produced. The overall yield of this process 
again has improved, from approximately 55% to 93% on a five-kilogram 
demonstration scale (Fortunak, 2014). 
 To address the challenge of cost-competitive production of APIs 
in South Africa, one of us, PW, and researchers at Nelson Mandela 
Metropolitan University (NMMU) are working to provide a step-change 
in pharmaceutical manufacturing technology that will increase the 
availability and affordability of APIs. This step-change will result from 
the continuous production of APIs in small, modular units known as 
flow reactors. Flow reactors operate continuously on a small scale, for 
extended periods of time. Production carried out on a 24/7 basis reduces 
the size of reactors needed for production and thereby reduces the capital 
investment needed for production start-ups. Although flow chemistry is 
engineering-intensive and the individual reactors are more expensive 
than traditional, chemical stirred tank reactors, this upfront investment 
in advanced science can create substantial efficiencies in manufacturing 
footprint and production costs as well as capital investment. Waste 
generation during flow processing can often be significantly less than 
for traditional ‘batch’ processing of APIs. 
 Compared to stirred batch reactor methodology, the benefits of MRT/
flow chemistry are:
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 increased reaction control and reproducibility by:  ●
 efficient mixing  ●
 accurate control of time, temperature and pressure  ●
 increased catalyst lifetime and activity  ●
 enhanced safety due to:  ●
 rapid dissipation of heat  ●
 low reactant volumes at any given time  ●
 real-time analytical evaluation  ●
 lower cost due to  ●
 higher chemical yield  ●
 reduced material use and waste generation  ●
 reduced investment  ●
 This system’s flexibility has the potential to reduce the time and risk 
associated with transferring technology from research into production. 
This methodology is being exploited profitably by fine chemical compa-
nies in Europe. The aim of this project is to exploit this technology to 
reduce cost of drugs of importance to South Africa making the country 
more self-reliant. In the first instance NMMU are focusing on three anti-
HIV drugs, but the technology could readily be applied to other drugs of 
relevance to African needs. 
 Ethiopia: Research on local sources of starch 
as an excipient 
 Excipients used in FPPs may originate from natural sources, chemical 
synthesis or biotechnology. Since excipients are ingested every time a 
patient takes an FPP, safety, quality and price are important. Most excipi-
ents are generally regarded as safe (GRAS) for humans because of a long 
history of use in the food, flavourings and cosmetics industries. One of 
us (TGM) is researching the development of inexpensive local sources of 
excipients in Ethiopia for pharmaceutical production, with a focus on 
starch and starch derivatives, gums and resins. 
 There is a huge potential for the development of new and alternative 
local sources of excipients in Africa. Starch is used as a component in 
the manufacture of pharmaceuticals, food, textiles, paper and adhesives. 
The use of native starch or its modified forms is based on its adhesive, 
thickening, gelling and film-forming properties. Starches are readily 
available, low cost and can be processed to provide high-quality mate-
rials of varying grades for a variety of uses. Although starch is a major 
component in most plants, the main commercial sources are the seeds 
Raising the Technological Level in Africa 141
of cereal grains (maize, wheat and rice), tubers (potato) and certain roots 
(sweet potato, cassava and arrow roots). Over the last ten years, native 
( enset ) starch has been produced on commercial scale in Ethiopia for the 
food and beverage industries. 
 The worldwide market for industrial starches is expanding, and the 
industrial trend is towards the use of commercially viable raw mate-
rials other than maize, wheat and potato, which have competing food 
uses. Some tropical plants including  enset ,  dioscorea , cassava and  godare 
have been investigated.  Enset starch extracted from  boulla provided a 
99% yield (recovery) of available starch on dry weight basis. Scanning 
electron microscopy (SEM) of  enset starch granules showed characteristic 
morphology that was somewhat angular and elliptical. Laser diffraction 
studies revealed normal granule size distribution with a mean particle 
size of 46 μm (Gebre-Mariam and Schmidt, 1996a). Evaluated as a 
binder and disintegrant for compressed tablets,  enset starch was found 
to compare favourably with potato and maize starches (Gebre-Mariam 
and Nikolayev, 1993; Gebre-Mariam and Schmidt, 1996b). 
 Super-disintegrants are modified polymers that rapidly absorb water 
and swell in the aqueous environment of the stomach. Sodium starch 
glycolate (SSG) is the sodium salt of the carboxymethyl ether of native 
starch. SSG rapidly absorbs water and swells, causing tablets and capsules 
containing these excipients to break apart rapidly, enhancing their 
release properties for improved drug absorption.  Enset starch was modi-
fied into sodium starch glycolate and evaluated as a super-disintegrant 
in compressed tablets. SSG of  enset starch was found to be at least as effi-
cient as commercial grades of SGG, Primojel ® or Croscarmellose sodium. 
In soluble tablet formulations, sodium starch glycolate of  enset was more 
efficient than Primojel ® or Ac-Di-Sol ® . Tablets prepared with sodium 
starch glycolate of  enset exhibited shorter disintegration times and faster 
rates of swelling and water uptake. Similarly, the sodium starch glyco-
late of  dioscorea starch was found to be more efficient than EXPT ® (the 
‘Explo-tab’ brand of SSG) in soluble and insoluble tablet formulations 
(Gebre-Mariam et al., 1996b). 
 Comparative studies of the starch in tablet formulations indicated 
 dioscorea starch has practically identical binding and disintegrating 
ability to that of potato starch (Gebre-Mariam and Schmidt, 1998). 
Drug release studies from matrix tablets revealed that the rate of release 
changed from rapid release to sustained release as the degree of substitu-
tion increased. Dissolution studies showed that  enset starch acetates with 
high degree of substitution could act as matrix-forming agents in tablets, 
where the release of a drug can be significantly sustained (Nigussu et al., 
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2013). Efforts are under way to progress the work for adoption in local 
pharmaceutical production. 
 Conclusion: building skills for API manufacture and 
drug discovery 
 African pharmaceutical companies largely employ excellent scien-
tists – their staff are often the equal of scientists anywhere. A major 
gap, however, is one of experience. The USFDA commonly notes that 
an appropriate combination of ‘education, training, and experience’ is 
needed to operate under GMP. Another challenge for pharmaceutical 
production is that African companies rarely are able to apply substan-
tial resources to developing new products. It is common for compa-
nies to purchase technical development packages from Indian generics 
producers as the source of their process descriptions. These packages 
are not nearly as detailed as needed for the full process understanding 
and control needed for SRA approvals. It is also difficult for African 
companies to expend equivalent resources on laboratory and pilot scale 
equipment and on preparing pilot- and commercial-scale development 
batches to optimize their manufacturing processes. 
 This chapter pinpoints two important strategies by which existing 
capabilities can be leveraged to support the emergence of a sustainable 
API, excipients and generic pharmaceutical industry on the African 
continent. Both of these approaches are suitable for implementation by 
regional centres of excellence (CoEs) in drug development and regula-
tory sciences. Regional CoEs are recognized by the PMPA and by the 
United Nations African Initiative for New Drugs and Diagnostics (ANDI) 
Program as important for developing African capabilities in pharmaceu-
tical innovation. 
 The first of these strategies is to develop education and training 
curricula at universities and academic Institutions. These programs must 
initially borrow from the experience of external experts to reduce the 
gap in hands-on experience in manufacturing technologies API, excipi-
ents and FPP as well as regulatory science. There are substantial numbers 
of African nationals working in important positions in global pharma-
ceutical companies today. Active recruitment of some of these experi-
enced scientists to ‘return home’ – a process known as braingain – could 
be an important point of leverage for promulgating, implementing 
and improving international standards for product development and 
SRA approvals. A number of African countries have courses in phar-
macy, industrial chemistry, fermentation technologies, microbiology, 
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biochemistry (including immunology) and process engineering, among 
others. As alluded to earlier, what is missing is hands-on industrial expe-
rience and learning-by-doing (DUI) mode of innovation. 
 A second strategy to promote African API, excipient and FPP devel-
opment is to fund regional CoEs to develop Technology Transfer 
Packages (TTPs) that enable pharmaceutical companies to implement 
quality-assured manufacturing of a specific API, excipient or FPP. If 
adequately funded, equipped and staffed with competent people, the 
CoEs could develop pharmaceutical manufacturing processes, analyt-
ical test methods and specifications for essential medicines. They can 
serve as clinical trial coordinators and knowledge brokers. With such 
an approach it should be feasible to sustainably raise the technological 
scope for locally manufacturing APIs, excipients and biologicals and to 
support a broader value chain of local pharmaceutical production on 
the continent. 
 Notes 
 1 .  See, for example, Bioclones (South Africa), manufacturing erythropoietin, 
 http://www.bioclones.co.za/ , and LaGray Chemical Company (Ghana), manu-
facturing azithromycin,  http://www.lagraychem.com/ . 
 2 .  See, for example, South Africa: Ketlaphela – South Africa Government’s ARV 
Manufacturing Project Enters Next Phase, all Africa, 16 May 2013,http://alla-
frica.com/stories/201305211581.html; Sarah Wild, ‘ARV plan bounces back’, 
 Mail & Guardian , 24 May 2013,  http://mg.co.za/article/2013–05–24–00-arv-
plan-bounces-back . 
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